Ryuji Furihata Selected Research

Major Depressive Disorder (Major Depressive Disorders)

3/2022	The characteristics of patients receiving psychotropic pro re nata medication at discharge for the treatment of schizophrenia and major depressive disorder: A nationwide survey from the EGUIDE project.
1/2022	Hypnotic medication use among inpatients with schizophrenia and major depressive disorder: results of a nationwide study.
9/2021	Characteristics of discharge prescriptions for patients with schizophrenia or major depressive disorder: Real-world evidence from the Effectiveness of Guidelines for Dissemination and Education (EGUIDE) psychiatric treatment project.
10/2019	Improvement of psychiatrists' clinical knowledge of the treatment guidelines for schizophrenia and major depressive disorders using the 'Effectiveness of Guidelines for Dissemination and Education in Psychiatric Treatment (EGUIDE)' project: A nationwide dissemination, education, and evaluation study.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Ryuji Furihata Research Topics

Disease

9	Schizophrenia (Dementia Praecox) 10/2022 - 08/2009
4	Major Depressive Disorder (Major Depressive Disorders) 03/2022 - 10/2019
4	Sleep Initiation and Maintenance Disorders (Insomnia) 01/2020 - 08/2009
2	Treatment-Resistant Schizophrenia 10/2022 - 01/2022
1	Mental Disorders (Mental Disorder) 01/2022
1	Colitis 10/2019
1	Mood Disorders (Mood Disorder) 10/2019
1	Disorders of Excessive Somnolence (Hypersomnia) 08/2012

Drug/Important Bio-Agent (IBA)

4	Antipsychotic Agents (Antipsychotics)IBA 10/2022 - 09/2021
3	Indicators and Reagents (Reagents)IBA 01/2020 - 08/2009
2	Clozapine (Clozaril)FDA LinkGeneric 10/2022 - 01/2022
2	Antidepressive Agents (Antidepressants)IBA 01/2022 - 09/2021
2	Anti-Anxiety Agents (Anxiolytics)IBA 01/2022 - 09/2021
2	Cholinergic Antagonists (Anticholinergics)IBA 01/2022 - 01/2022
2	Hypnotics and Sedatives (Sedatives)IBA 01/2022 - 09/2021
1	N-acetyltryptophanamide (NATA)IBA 03/2022
1	Anticonvulsants (Antiepileptic Drugs)IBA 01/2022
1	Aripiprazole (Abilify)FDA Link 09/2021
1	blonanserinIBA 09/2021
1	Olanzapine (Zyprexa)FDA Link 09/2021
1	Quetiapine Fumarate (Seroquel)FDA Link 09/2021
1	Risperidone (Risperdal Consta)FDA LinkGeneric 09/2021
1	Brain-Derived Neurotrophic Factor (BDNF)IBA 01/2020
1	Dextran SulfateIBA 10/2019
1	Silver Sulfadiazine (SSD)FDA LinkGeneric 08/2012
1	Lysergic Acid Diethylamide (LSD)IBA 08/2012

Therapy/Procedure

2	Polypharmacy 03/2022 - 09/2021
2	Therapeutics 01/2020 - 10/2019
1	Drug Therapy (Chemotherapy) 03/2022